APR 27, 2026 · REGULATORY LABEL UPDATE
FDA supplemental approval: Lenalidomide (REMS)
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative clinical outcomes.
Reported
Approval date2026-04-27
Strengths approved5 mg, 15 mg, 20 mg, 25 mg